NGNE Stock — Neurogene Inc.: Metrics

Market overview

2 metrics

Share price

$38.36

Market cap

$752.63M

Price action

19 metrics

Price change (1W)

-0.1%

Price change (30D)

+11.5%

Price change (3M)

+46.3%

Price change (6M)

+60.4%

Price change (YTD)

+86.2%

Price change (1Y)

+95.3%

Trailing year

Price change (5Y)

—

52-week high

$42.84

52-week low

$16.37

Change from 52-week high

-10.5%

Change from 52-week low

+134.3%

Annualized volatility

83.0%

Beta

1.6

RSI (14D)

55.1

Price vs SMA 50

+6.3%

Price vs SMA 200

+47.7%

Avg volume (3M)

233,833

Relative volume

1.1

Average dollar volume

$8.25M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

20.01M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

3.5

reciprocal yield 28.7%

FCF yield

-11.6%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-14.7%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2025-08-11

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$121.35M

Net income (TTM)

−$111.11M

Trailing 12 months

Diluted EPS (TTM)

$-5.03

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-4,354.21

Growth

11 metrics

Revenue growth YoY

-100.0%

Year over year

Net income growth YoY

—

Revenue (TTM)

$0

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+7.1%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-51.2%

Return on assets

-45.5%

Debt / equity

—

Current ratio

10.6

EBITDA (TTM)

−$118.19M

Free cash flow (TTM)

−$87.71M

Quick ratio

10.6

Interest coverage

-60,673.5

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$225.39M

Latest balance sheet

Cash & equivalents

$112.48M

Total assets

$244.36M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$86.82M

Capital expenditures (TTM)

$890,000

R&D (TTM)

$88.50M

SG&A (TTM)

—

Stock compensation (TTM)

$18.22M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

113

13F filer change QoQ

+15

Institutional ownership

87.2%

Short interest

3 metrics

Short interest

15.2%

Latest settlement · 16.8 days to cover

Days to cover

16.8d

Short-squeeze score

70 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$339,962

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

NGNE · Neurogene Inc.

NGNE metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search